Media Library

News Features

Breast Cancer Canada CEO Kimberly Carson discusses breast cancer risk factors on CTV.

Breast Cancer Canada CEO Kimberly Carson and Breast Cancer Survivor Charlene Newland appear on CP24 Toronto to discuss World Cancer Day.

Breast Cancer Canada’s Progress CONNECT Website Launch.

Breast Cancer Canada CEO Kimberly Carson and Breast Cancer Survivor Robyn Goldman appear on CP24 Toronto to discuss early detection.

Breast Cancer Canada CEO Kimberly Carson appears on CP24 Toronto to discuss the $3 Million Dollar Research Grant to Princess Margaret Cancer Centre.

Breast Cancer Canada CEO Kimberly Carson appears on CTV Calgary News to discuss the $3 Million Dollar Research Grant to Princess Margaret Cancer Centre.

Breast Cancer Canada Board Chair, Shaniah Leduc on CTV News Toronto discussing US Breast Cancer screening age reductions.

Breast Cancer Canada Board Chair, Shaniah Leduc on CP 24Toronto discussing US Breast Cancer screening age reductions.

Breast Cancer Canada CEO Kimberly Carson discusses BCC’s $3 Million Dollar Research Donation to Princess Margaret Cancer Centre.

SABCS 2023 Highlights

BCC was honoured to once again bring together oncologists, researchers, clinicians and industry leaders for an evening of connection and special announcements.

We just heard about the groundbreaking HER2CLIMB-02 study, involving HER2-positive metastatic breast cancer patients. Researchers unveiled exciting advancements in treating Brain Metastases.

Shared decision-making between the patient and the oncologist is essential in breast cancer care.

Breast Cancer Canada was pleased to hear the findings from a late-breaking presentation at SABCS, which featured analysis from the MONARCH 3 study.

Researchers shared data on two new potential combination treatment regimens for hormone receptor (HR)-positive, HER2-positive metastatic breast cancer that wouldn’t require patients to get chemotherapy.

Roche’s promising study, INAVO120, focused on a new breast cancer treatment. They tested a combo of new drug Inavolisib with currently available Palbociclib and Fulvestrant.

ESMO 2023 Highlights

Breast Cancer Canada is live from ESMO Congress – where global experts in cancer research are presenting the latest in new treatment results from clinical trials. Exciting results were shared today by @merck.

We are excited to share that @elilillyco presented their 5-year follow up results from the early-stage monarchE study using the medication VERZENIO (Abemaciclib).

This study is shedding light on the use of TRODELVY (Sacituzumab Govitecan) for treating metastatic triple-negative breast cancer (mTNBC).

Breast Cancer Canada is excited to share a breakthrough in breast cancer research, thanks to work of @AstraZeneca and @daiichisankyo.

Novartis and their RIGHT CHOICE Metastatic Breast Cancer Study is showing some significant results in breast cancer patients with HR/PR + type that has spread to internal organs.